α4β1/7 Integrin Ligand Conjugates for Targeted Brain Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for delivering therapeutic, prophylactic, or diagnostic compounds in vivo lack specificity, leading to unintended consequences such as off-target effects, and there is a need for more efficient targeting of compounds like oligonucleotides and small molecules to specific cell types, particularly those expressing the α4β1/7 integrin receptor in the brain.
Innovation Solution
Development of compounds comprising α4β1/7 integrin receptor ligands conjugated with linker moieties and therapeutic, prophylactic, or diagnostic agents, such as oligonucleotides, peptides, or small molecules, to selectively target and deliver agents to cells expressing the α4β1/7 integrin receptor in brain regions like the frontal cortex, striatum, cerebellum, brain stem, hippocampus, and spinal cord.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are administered in vivo without targeting ligands, then the compounds can be delivered systemically, but off-target effects occur and delivery specificity is poor
Solution Approach 1:
The patent employs targeting ligands as intermediary molecules that mediate between the therapeutic compound and the target cell. These ligands bind to specific receptors (such as α4β1/7 integrin) on the cell surface, facilitating selective delivery of the compound to the desired target while preventing off-target effects. The ligand acts as a bridge that ensures the compound reaches only the intended cellular destination.
2Reliability
If targeting ligands are used to deliver compounds to specific cells, then delivery specificity improves, but the compound structure becomes more complex
Solution Approach 1:
The patent divides the compound into distinct functional segments: a targeting ligand portion responsible for cell recognition and binding, a linker portion that connects the ligand to the therapeutic payload, and the therapeutic compound itself. This segmentation allows each component to be optimized independently - the ligand for specific binding affinity, the linker for stability and flexibility, and the payload for therapeutic activity - while maintaining overall structural organization.
Solution Approach 2:
The targeting ligand framework can be designed to recognize multiple target receptors or cell types, providing multi-functionality. The same ligand structure can be conjugated with different therapeutic compounds (oligonucleotides, small molecules, proteins), making the delivery system universally applicable to various therapeutic agents while maintaining specific targeting capability.
3Adaptability or versatility
If oligonucleotides are used to modulate nucleic acid expression, then gene expression can be controlled, but delivery to specific brain regions remains challenging
Solution Approach 1:
The patent uses α4β1/7 integrin receptor ligands as intermediary carriers that facilitate the delivery of oligonucleotide therapeutics to specific brain regions. The ligand binds to integrin receptors that are selectively expressed on the surface of neurons and glial cells in the target brain area, enabling the oligonucleotide to reach its cellular destination across the blood-brain barrier and within specific neural tissues.
Solution Approach 2:
The patent exploits the local quality principle by utilizing the selective expression of α4β1/7 integrin receptors in specific brain regions and cell types. The targeting ligand is designed to recognize this localized receptor distribution pattern, ensuring that the oligonucleotide therapeutic is delivered preferentially to the intended brain region (such as frontal cortex, striatum, cerebellum, hippocampus, or spinal cord) rather than distributed uniformly throughout the brain.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively deliver agents to specific brain cells, modulating nucleic acid expression or activity, treating diseases, and providing targeted therapeutic or diagnostic benefits while minimizing off-target effects.
Implementation Method 1
a compound comprises an α4β1/7 integrin receptor ligand and one or more linker moieties for attachment to a therapeutic, prophylactic, or diagnostic agent
Data Source
AI summary
Provided herein are α4β1/7 integrin receptor ligand-containing compounds, methods of delivering said compounds, and methods of treating diseases, disorders, and symptoms (e.g., central nervous system diseases, disorders, and symptoms) in a subject using said compounds.